General Information of Drug (ID: DM7O5WS)

Drug Name
N-(4-hydroxybenzyl)icosa-5,8,11,14-tetraenamide Drug Info
Synonyms CHEMBL434069; N-(4-hydroxybenzyl)icosa-5,8,11,14-tetraenamide; BDBM50054470; (5Z,8Z,11Z,14Z)-Icosa-5,8,11,14-tetraenoic acid 4-hydroxy-benzylamide
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10811495
TTD Drug ID
DM7O5WS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [2]
Thiopental DMGP8AX Anaesthesia 9A78.6 Approved [3]
JNJ-42165279 DM72GZO Anxiety disorder 6B00-6B0Z Phase 2 [4]
SSR411298 DMGTB2Q Major depressive disorder 6A70.3 Phase 2 [5]
IW-6118 DMP42W1 Inflammation 1A00-CA43.1 Phase 2 [6]
PF-04457845 DMPRYU1 Liver disease DB90-BD99 Phase 2 [7]
IPI-940 DMEIM5G Pain MG30-MG3Z Phase 1 [8]
PMID29053063-Compound-11d DMDRK68 N. A. N. A. Patented [9]
Piperazine carbamic compound 1 DMZSYU4 N. A. N. A. Patented [9]
Piperazine carbamic compound 2 DMMQ0ZO N. A. N. A. Patented [9]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Guanfacine extended release DMB1CZ8 Attention deficit hyperactivity disorder 6A05.Z Approved [10]
NABILONE DMVRYT2 Insomnia 7A00-7A0Z Approved [11]
GW-42004 DMY3KSU Lipid metabolism disorder 5C52.Z Phase 2 [12]
KHK-6188 DMF6CTI Neuropathic pain 8E43.0 Phase 2 [13]
LY-2828360 DMO8IEZ Pain MG30-MG3Z Phase 2 [13]
APD371 DM3XT5V Crohn disease DD70 Phase 2 [14]
S-777469 DMZGNOJ Atopic dermatitis EA80 Phase 2 [15]
842166X DMOV0AP Pain MG30-MG3Z Phase 2 [16]
Beta-caryophyllene DM7583A Pain MG30-MG3Z Phase 2 [17]
Vicasinabin DMF16CU Diabetic retinopathy 9B71.0 Phase 2 [18]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [19]
NABILONE DMVRYT2 Insomnia 7A00-7A0Z Approved [11]
Orlistat DMRJSP8 Obesity 5B81 Approved [20]
SR141716A DMCO5JZ Obesity 5B81 Approved [21]
Tebipenem DMVSX6O Urinary tract infection GC08 Phase 3 [22]
Conatumumab DM2UOSN Colorectal cancer 2B91.Z Phase 2 [23]
GW-42004 DMY3KSU Lipid metabolism disorder 5C52.Z Phase 2 [12]
SR-147778 DMNAECP Obesity 5B81 Phase 2 [24]
Nimacimab DM21Z68 Diabetic nephropathy GB61.Z Phase 2 [25]
AEF0117 DMQ1GH4 Marijuana use disorder 6C41 Phase 2 [26]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cannabinoid receptor 1 (CB1) TT6OEDT CNR1_HUMAN Inhibitor [1]
Cannabinoid receptor 2 (CB2) TTMSFAW CNR2_HUMAN Inhibitor [1]
Fatty acid amide hydrolase (FAAH) TTDP1UC NOUNIPROTAC Inhibitor [1]

References

1 New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5.
2 Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
3 The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003 Jul;139(5):1005-13.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
6 The Discovery and Development of Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Bioorg Med Chem Lett. 2011 August 15; 21(16): 4674-4685.
7 Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett. 2011 Feb 10;2(2):91-96.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1400).
9 A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
10 Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81.
11 Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
12 Company report (Gwpharm)
13 Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2).
14 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
15 Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2009 Mar;14(1):165-79.
16 The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies. Yao Xue Xue Bao. 2013 Sep;48(9):1436-49.
17 The cannabinoid CB1 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol. 2014 Apr;24(4):608-20.
18 Clinical pipeline report, company report or official report of Roche
19 Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
20 Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
21 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
22 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
23 Clinical pipeline report, company report or official report of AstraZeneca (2009).
24 Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
25 Clinical pipeline report, company report or official report of Bird Rock Bio.
26 Clinical pipeline report, company report or official report of Affimed Therapeutics.